title: Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
abstract: OBJECTIVE
  The association of BRCA2 polymorphisms at codon 372 [Asn (N)/His (H)]and codon 784 [Met (M)/Val (V)] with breast cancer risk was evaluated in Japanese women. In addition, the prognostic significance of these polymorphisms was studied in breast cancer patients.
  
  
  METHODS
  A case-control study was conducted to examine the association of the BRCA2 N/H372 polymorphism and M/V 784 polymorphism with breast cancer risk (cases = 149, controls = 154). The prognostic significance of these polymorphisms was evaluated in 139 patients with primary breast cancer.
  
  
  RESULTS
  No significant association was observed between the N/H372 polymorphism and breast cancer risk. In contrast, a significant increase in breast cancer risk (odds ratio, 2.03; 95% confidence interval, 1.07-3.87) was observed in carriers of the variant allele (V784) of the M/V784 polymorphism as compared with noncarriers after adjustment for the classical risk factors, age, family history, parity, body mass index, and so forth. Among breast cancer patients, various clinicopathological parameters including menopausal status, tumor size, lymph node status, histological grade, and estrogen-receptor status were not significantly different between the carriers and noncarriers of the variant allele with regard to both N/H372 and M/V784 polymorphisms. The N/H 372 polymorphism was not significantly associated with patient prognosis. On the other hand, breast cancer patients carrying the variant allele of M/V784 polymorphism showed a significantly (P = 0.014) lower 3-year disease-free survival rate (63%) than noncarriers (92%). Multivariate analysis has revealed that the M/V784 polymorphism is a significant prognostic factor, being independent of the other conventional prognostic factors such as lymph node status and estrogen receptor status.
  
  
  CONCLUSIONS
  These results suggest that the M/V784 polymorphism, but not the N/H372 polymorphism, would be useful in the selection of women at high risk for developing breast cancer and would also serve as a clinically useful prognostic factor in breast cancer patients.
authors.affiliation: Department of Surgical Oncology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Ishitobi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Miyoshi
authors.forename: Akiko
authors.initials: A
authors.lastname: Ando
authors.forename: Seiichi
authors.initials: S
authors.lastname: Hasegawa
authors.forename: Chiyomi
authors.initials: C
authors.lastname: Egawa
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tamaki
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
authors.forename: Shinzaburo
authors.initials: S
authors.lastname: Noguchi
mesh_terms: D000483:Alleles; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D016022:Case-Control Studies; D003062:Codon; D018572:Disease-Free Survival; D005260:Female; D005838:Genotype; D006801:Humans; D015999:Multivariate Analysis; D011110:Polymorphism, Genetic; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D012307:Risk Factors; D013997:Time Factors
chemical_list: D024682:BRCA2 Protein; D003062:Codon; D011960:Receptors, Estrogen